Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsYongge Liu, Junichi Kambayashi
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.
Claims17
A method for reducing cardiotoxicity and/or improving survival from anthracycline chemotherapy comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as the active ingredient, administered simultaneously with or prior to anthracycline administration.
A pharmaceutical composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof for reducing cardiotoxicity and/or improving survival from anthracycline chemotherapy, for administering simultaneously or prior to anthracycline administration.
Dependencies are inferred from the claim text.